| 000 | 01052 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250516023013.0 | ||
| 264 | 0 | _c20120927 | |
| 008 | 201209s 0 0 eng d | ||
| 022 | _a1873-7064 | ||
| 024 | 7 |
_a10.1016/j.neuropharm.2011.01.030 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLabrie, Viviane | |
| 245 | 0 | 0 |
_aContributions of the D-serine pathway to schizophrenia. _h[electronic resource] |
| 260 |
_bNeuropharmacology _cMar 2012 |
||
| 300 |
_a1484-503 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aGlutamic Acid _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aReceptors, N-Methyl-D-Aspartate _xmetabolism |
| 650 | 0 | 4 |
_aSchizophrenia _xetiology |
| 650 | 0 | 4 |
_aSerine _xmetabolism |
| 650 | 0 | 4 | _aSignal Transduction |
| 700 | 1 | _aWong, Albert H C | |
| 700 | 1 | _aRoder, John C | |
| 773 | 0 |
_tNeuropharmacology _gvol. 62 _gno. 3 _gp. 1484-503 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.neuropharm.2011.01.030 _zAvailable from publisher's website |
| 999 |
_c20573502 _d20573502 |
||